ClinicalTrials.gg
RecruitingNCT06483269Updated Jul 4, 2025

Homologus PRP in the Infiltrative Treatment of Knee Osteoarthritis in Young Athletic Patients

An interventional study of PRP infiltration in Knee Osteoarthritis, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Oct 2023, registered Jun 2024).
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli — 13 open to participants now, 13 under way, none of them phase 3. Osteoarthritis, Knee · Istituto Ortopedico Rizzoli.

Planned enrollment
18th of 25
30 · median 50
Started
2023
with 4 others
No phase
21 of 31
11 open now
Primary completion
2026-09
later than 4 of 12 live
Registered
28th of 31
by date

Among the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, this one is the 18th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2023, is one of 21 with no phase, reaches primary completion later than 4 of the 12 other live ones, and was the 28th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

13 of the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, or all of them as a file.
02

Study summary

The study consists of 3 phases (enrollment, infiltrative procedure, and controls):

  • Identification by specialized orthopedic medical staff belonging to the SC Orthopedic and Trauma Clinic II of the Rizzoli Orthopedic Institute of subjects who meet the study inclusion criteria. Signing of informed consent form and completion of evaluation questionnaires.
  • infiltrative procedure
  • Patients will be clinically evaluated before the infiltration procedure and at 1, 3, 6, and 12 months after treatment by trained medical personnel (outcome assessors). Questionnaires will be administered for clinical evaluations before treatment and at these clinical checkups during follow-up. Any adverse events to treatment will also be assessed during follow-up visits. The duration and extent of joint swelling and pain following infiltration will be reported, and any drug therapies taken by the patient will be recorded.
03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients, both sexes, with symptomatic knee osteoarthritis with:
  • Age: 18-40 years;
  • Unilateral involvement;
  • Signs and symptoms of knee osteoarthritis;
  • Radiographic or MRI signs of degenerative pathology of knee cartilage (Kellgren-Lawrence grade 1-3);
  • Ability and consent of patients to actively participate in clinical follow-up;
  • Signature of ;
  • Pain ≥ 4 on VAS s

Exclusion criteria

Exclusion Criteria:

  • Patients unable to express consent;
  • Patients undergoing intra-articular infiltration of other substance in the previous 6 months;
  • Patients undergoing knee surgery in the previous 12 months;
  • Patients with malignant neoplasms;
  • Patients with rheumatic diseases;
  • Patients with uncontrolled metabolic diseases;
  • Patients with hematological diseases (coagulopathies);
  • Patients abusing alcoholic beverages, drugs or medications;
  • Knee trauma treated in the previous 6 months.
  • Other conditions that may interfere with the evaluation of OA treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    infiltrative procedure

    Procedure: PRP infiltration

Interventions

  • ProcedurePRP infiltration

    a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician. It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site. PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat. PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations.

06

What researchers measure

Primary outcomes

  1. International Knee Documentation Committee score

    This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathology. The questionnaire examines 3 categories: symptoms, sports activity, and knee function.

    Time frame: 6 months

Secondary outcomes

  1. International Knee Documentation Committee score

    This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathology. The questionnaire examines 3 categories: symptoms, sports activity, and knee function.

    Time frame: baseline, 1, 3, 6, 12 months

  2. Tegner Activity Level Scale

    It is a questionnaire to find out the patient's level of physical activity

    Time frame: baseline, 1, 3, 6, 12 months

  3. Knee Injury and Osteoarthritis Outcome Score

    The full questionnaire consists of five subscales and they cover: pain (9 items), symptoms (7 items of which two relate to stiffness), functions and activities of daily living (17 items) physical function, sports activities and leisure (5 items) and quality of life in relation to the knee (4 items). All items in the relevant subscales have the same response mode, use a 5-point Likert scale, and each question is assigned a score from 0 to 4, where 0 indicates "no difficulty" and 4 "a severe difficulty). Score range 0-100 for each subscale.

    Time frame: baseline, 1, 3, 6, 12 months

  4. Visual Analogue Scale

    visual analog scale consisting of a straight line segment (10 cm length), the ends of which correspond to "no pain" and "the strongest pain imaginable"

    Time frame: baseline, 1, 3, 6, 12 months

  5. objective parameter

    range of motion and bilateral trans patellar and supra patellar circumferences for comparative analysis.

    Time frame: baseline, 1, 3, 6, 12 months

  6. Patient Acceptable Symptom State

    Valuable tool for assessing patient satisfaction considering the patient's current degree of pain, function, and daily activity.

    Time frame: baseline, 1, 3, 6, 12 months

  7. Expectations of treatment efficacy

    The patient should indicate at baseline what benefits he or she expects from the treatment.

    Time frame: baseline

  8. Overall judgment on treatment

    The patient should indicate the degree of satisfaction related to the treatment performed at each follow-up.

    Time frame: baseline, 1, 3, 6, 12 months

Other outcomes

  1. Tolerability assessment parameters:

    All adverse events will be reported by filling out "Adverse event report forms" that will be kept with each patient's CRF (Case Report Form). The latter will document all medications taken additionally by the patient for pain control, indicating brand name, generic name, start and end of intake, and daily dose. Serious adverse events will be reported as per company procedure and the Ethics Committee will be informed, which will rule on whether patient enrollment should be discontinued.

    Time frame: baseline, 1, 3, 6, 12 months

  2. Platelet-rich plasma-Homologous (PRP-O) evaluation parameters

    The quality of the administered Platelet-rich plasma- Homologous (PRP-O) will be assested by using standard blood parameters data as hematological control.

    Time frame: baseline, 1, 3, 6, 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Everts PA, Knape JT, Weibrich G, Schonberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006 Jun;38(2):174-87. PubMed 16921694 ↗
  • Sanchez AR, Sheridan PJ, Kupp LI. Is platelet-rich plasma the perfect enhancement factor? A current review. Int J Oral Maxillofac Implants. 2003 Jan-Feb;18(1):93-103. PubMed 12608674 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Sep 2026, 35 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 35 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2024
First posted
Jul 3, 2024
StartActual
Oct 10, 2023
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06483269
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Oct 10, 2023
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jul 4, 2025

Study contacts

Mirco Lo Presti, MD
Contact
mirco.lopresti@ior.it
0516366 ext. 084

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion